Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 130
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | ||
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | ||
| NCT02500901 | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | ||
| NCT00216203 | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | ||
| NCT06392841 | Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations | ||
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | ||
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | ||
| NCT06728410 | A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | ||
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | ||
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | ||
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | ||
| NCT00572572 | Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors | ||
| NCT06503614 | A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | ||
| NCT00730353 | Sutent + Taxol for Advanced Esophageal Cancer | ||
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis | ||
| NCT03737123 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | ||
| NCT00537173 | Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer | ||
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | ||
| NCT02375672 | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | ||
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC | ||
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | ||
| NCT00216099 | Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer | ||
| NCT05442216 | Tagraxofusp and Azaxitadine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | ||
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | ||
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | ||
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | ||
| NCT03448718 | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | ||
| NCT04848337 | Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | ||
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | ||
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements | ||
| NCT03528408 | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | ||
| NCT00216060 | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy | ||
| NCT00216073 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | ||
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | ||
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | ||
| NCT00216164 | Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ||
| NCT00706641 | Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder | ||
| NCT00472589 | A Biological Sample Collection Protocol of Women With and Without Breast Cancer | ||
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | ||
| NCT00319735 | Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas | ||
| NCT00216112 | Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer | ||
| NCT03871153 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer | ||
| NCT00859339 | Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | ||
| NCT00216047 | PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | ||
| NCT03960151 | Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy | ||
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | ||
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | ||
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | ||
| NCT00367601 | Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer |
